

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

## The signaling lipid sphingosine 1-phosphate regulates mechanical pain

**Authors and Affiliations:** Rose Z. Hill<sup>1</sup>, Benjamin Hoffman<sup>2,3</sup>, Takeshi Morita<sup>1#</sup>, Stephanie M. Campos<sup>4‡</sup>, Ellen A. Lumpkin<sup>2, 4</sup>, Rachel B. Brem<sup>5, 6</sup>, Diana M. Bautista<sup>1, 4, 7, 8\*</sup>

1. Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720, USA.
2. Department of Physiology & Cellular Biophysics, Columbia University College of Physicians & Surgeons, New York, NY 10032
3. Medical Scientist Training Program, Columbia University, New York, NY 10032
4. Neurobiology Course, Marine Biological Laboratory, Woods Hole, MA
5. Department of Plant and Microbial Biology, University of California, Berkeley, CA 94720, USA.
6. Buck Institute for Research on Aging, Novato, CA 94945, USA.
7. Helen Wills Neuroscience Institute, University of California, Berkeley, CA 94720, USA.
8. Lead Contact

# Current Address: Rockefeller University, New York, NY 10065, USA.

‡ Current Address: Indiana University, Bloomington, IN 47405, USA.

\* Correspondence: [dbautista@berkeley.edu](mailto:dbautista@berkeley.edu)

## 40 Abstract

41 Somatosensory neurons mediate responses to diverse mechanical stimuli, from innocuous  
42 touch to noxious pain. While recent studies have identified distinct populations of A  
43 mechanonociceptors (AMs) that are required for mechanical pain, the molecular underpinnings  
44 of mechanonociception remain unknown. Here, we show that the bioactive lipid sphingosine 1-  
45 phosphate (S1P) and S1P Receptor 3 (S1PR3) are critical regulators of acute  
46 mechanonociception. Genetic or pharmacological ablation of S1PR3, or blockade of S1P  
47 production, significantly impaired the behavioral response to noxious mechanical stimuli, with no  
48 effect on responses to innocuous touch or thermal stimuli. These effects are mediated by fast-  
49 conducting A $\delta$  mechanonociceptors, which displayed a significant decrease in  
50 mechanosensitivity in S1PR3 mutant mice. We show that S1PR3 signaling tunes  
51 mechanonociceptor excitability via modulation of KCNQ2/3 channels. Our findings define a new  
52 role for S1PR3 in regulating neuronal excitability and establish the importance of S1P/S1PR3  
53 signaling in the setting of mechanical pain thresholds.

54

## 55 Introduction

56 Pain is a complex sensation. It serves to protect organisms from harmful stimuli, but can also  
57 become chronic and debilitating following tissue injury and disease. Distinct cells and molecules  
58 detect noxious thermal and mechanical stimuli. Thermal pain is detected by thermosensitive  
59 TRP channels in subsets of nociceptors<sup>1-4</sup>, and gentle touch is detected by Piezo2 channels in  
60 low-threshold mechanoreceptors (LTMRs)<sup>5-7</sup>. A $\delta$  high-threshold mechanoreceptors (HTMRs)  
61 have been shown to play a key role in responses to painful mechanical stimuli<sup>8-10</sup>.

62

63 Recent studies have shown that there are at least two populations of HTMRs that mediate  
64 responses to noxious mechanical stimuli. The *Npy2r*<sup>+</sup> subpopulation of HTMRs mediates fast

65 paw withdrawal responses to pinprick stimulation and terminate as free nerve endings in the  
66 epidermis<sup>11</sup>. The *Calca*+ subpopulation of circumferential-HTMRs respond to noxious force and  
67 hair pulling, and terminate as circumferential endings wrapped around guard hair follicles<sup>12</sup>.  
68 Additionally, somatostatin-expressing interneurons of laminae I-III in the dorsal horn of the  
69 spinal cord receive input from nociceptors and are required for behavioral responses to painful  
70 mechanical stimuli<sup>13</sup>. Despite these advances in defining the cells and circuits of mechanical  
71 pain, little is known about the molecular signaling pathways in mechanonociceptors.

72

73 Here, we show that the bioactive signaling lipid sphingosine 1-phosphate (S1P) is required for  
74 mechanical pain. Mice lacking the S1P receptor S1PR3 display striking and selective deficits in  
75 behavioral responses to noxious mechanical stimuli. Likewise, peripheral blockade of S1PR3  
76 signaling or S1P production impairs mechanical sensitivity. We found that S1P constitutively  
77 enhances the excitability of A mechanonociceptors (AMs) via closure of KCNQ potassium  
78 channels to tune mechanical pain sensitivity. The effects of S1P are completely dependent on  
79 S1PR3. Our findings uncover an essential role for S1P signaling in noxious mechanosensation.

80

## 81 Results

82 To identify candidate genes underlying mechanosensation, we previously performed  
83 transcriptome analysis of the sensory ganglia innervating the ultra-sensitive tactile organ (the  
84 star) of the star-nosed mole<sup>14</sup>. Immunostaining revealed the tactile organ is preferentially  
85 innervated by myelinated A $\delta$  fibers<sup>14</sup>. While our original analysis focused on ion channels  
86 enriched in the neurons of the star organ, our dataset also revealed enrichment of several  
87 components of the S1P pathway, including S1PR3. Likewise, single-cell RNA seq of mouse  
88 DRG neurons revealed expression of *S1pr3* in neurofilament H-expressing myelinated

89 mechanoreceptors<sup>15</sup>, which includes A $\beta$  as well as the A $\delta$  neuronal populations. Thus, we set  
90 out to define the role of S1P signaling and S1PR3 in somatosensory mechanoreceptors.

91

### 92 **S1PR3 mediates acute mechanical pain**

93 We first examined a variety of somatosensory behaviors in mice lacking S1PR3<sup>16</sup>  
94 (*S1pr3<sup>tm1Rlp/Mmnc</sup>*; referred to herein as *S1pr3<sup>-/-</sup>*). We initially investigated baseline responses to  
95 mechanical stimuli. *S1pr3<sup>-/-</sup>* mice displayed a dramatic loss of mechanical sensitivity (Fig. 1A),  
96 as von Frey paw withdrawal thresholds were significantly elevated in *S1pr3<sup>-/-</sup>* mice relative to  
97 *S1pr3<sup>+/+</sup>* and *S1pr3<sup>+/-</sup>* littermates (mean thresholds: 1.737 g vs. 0.736 and 0.610 g, respectively).  
98 Moreover, *S1pr3<sup>-/-</sup>* mice demonstrated decreased responses to a range of noxious tactile stimuli  
99 (2-6 g; Fig. 1B) and to noxious pinprick stimulation (Fig. 1C), but normal responsiveness to  
100 innocuous tactile stimuli (0.6-1.4g; Fig. 1B). *S1pr3<sup>-/-</sup>* mice exhibited normal tape removal  
101 attempts<sup>6</sup> (Fig. 1D), righting reflexes (Fig. S1A), radiant heat withdrawal latencies (Fig. S1B),  
102 and itch-evoked scratching<sup>17</sup> (Fig. S1C). These results demonstrate a selective role for S1PR3  
103 in acute mechanical pain.

104

105 As a complement to our analysis of somatosensation in *S1pr3<sup>-/-</sup>* animals, we employed a  
106 pharmacological approach, using the S1PR3-selective antagonist TY 52156 (TY). Similar to the  
107 phenotype of knockout animals, intradermal injection of 500  $\mu$ M TY into the mouse hindpaw (the  
108 site of testing) triggered a rapid and significant elevation in von Frey paw withdrawal thresholds  
109 (Fig. 1E) and decreased responsiveness to noxious (2-6 g), but not innocuous (0.6-1.4g), tactile  
110 stimuli (Fig. 1F). In contrast, blockade of S1PR1 with the selective antagonist W146 had no  
111 effect on mechanical thresholds (Fig. 1E). Overall, these data show that S1PR3 signaling sets  
112 mechanical pain sensitivity.

113

114

115 **Endogenous S1P mediates acute mechanical pain**

116 We next asked whether peripheral S1P was required for the S1PR3-dependent effects on  
117 mechanosensation. We decreased S1P levels via injection of the sphingosine kinase inhibitor  
118 SKI II to block local production of S1P<sup>18</sup> or elevated S1P levels via intradermal injection of S1P  
119 and measured behaviors 30 minutes after injection. Decreasing local S1P levels significantly  
120 reduced mechanical sensitivity (Fig. 2A), comparable to the hyposensitivity phenotype observed  
121 in *S1pr3*<sup>-/-</sup> mice (Fig. 1A). Again, similar to what was observed in *S1pr3*<sup>-/-</sup> animals (Fig. S1B),  
122 peripheral blockade of S1PR3 or S1P production had no effect on thermal sensitivity (Fig. S1D).  
123 Surprisingly, injecting exogenous S1P (10 μM; maximum solubility in saline vehicle) had no  
124 effect on mechanical sensitivity (Fig. 2A-B). However, as previously reported<sup>19</sup>, S1P injection  
125 triggered thermal hypersensitivity (data not shown) demonstrating that the lack of effect on  
126 mechanical hypersensitivity is not due to problems with S1P delivery or degradation. Although  
127 quantification of native S1P levels in skin is inaccurate owing to avid lyase activity<sup>20</sup>, our data  
128 establish that baseline S1P levels are sufficient to maximally exert their effect on S1PR3-  
129 dependent mechanical pain, such that increased levels of S1P do not evoke mechanical  
130 hypersensitivity, but diminished S1P leads to mechanical hyposensitivity. These data show that  
131 constitutive S1PR3 signaling is required for normal mechanosensitivity.

132

133 **S1PR3 is expressed in A mechanonociceptors**

134 We next aimed to characterize the somatosensory neuron subtypes expressing *S1pr3* as a  
135 window onto the role of S1PR3 in acute mechanical pain. We used *in situ* hybridization (ISH)  
136 with a specific *S1pr3* probe to examine expression patterns of *S1pr3*. In our experiments, 43%  
137 of cells from wild-type dorsal root ganglia (DRG) expressed *S1pr3* (Fig. 3A; top, Fig. 3E). We  
138 observed no reactivity in DRG isolated from *S1pr3*<sup>-/-</sup> mice (Fig. 3A; bottom), and no significant  
139 differences in the distribution of cell sizes between *S1pr3*<sup>-/-</sup> and *S1pr3*<sup>+/+</sup> ganglia ( $p = 0.18$ ;  
140 Kolmogorov-Smirnov type II test), suggesting no loss of major neuronal subtypes. While a

141 previous study using antibody staining concluded that S1PR3 protein was expressed by all DRG  
142 neurons<sup>21</sup>, we found that anti-S1PR3 antibodies showed broad immunoreactivity in DRG from  
143 mice lacking S1PR3 (data not shown).

144

145 Co-ISH revealed that a population of *S1pr3*<sup>+</sup> neurons represents A $\delta$  mechanonociceptors  
146 (AMs). These cells were medium-diameter ( $25.9 \pm 4.5 \mu\text{m}$ ) and expressed *Scn1a* (39.9% of all  
147 *S1pr3*<sup>+</sup>; Fig. 3B-C), a gene that encodes the Nav1.1 sodium channel which mediates  
148 mechanical pain in A $\delta$  fibers<sup>10</sup>, as well as *Npy2r* (20.4% of all *S1pr3*<sup>+</sup>; Fig. 3B-C), a marker of a  
149 specialized subset of mechanonociceptive A fibers<sup>7</sup>. *S1pr3* was expressed in 70.6% of *Scn1a*<sup>+</sup>  
150 cells and 72% of *Npy2r*<sup>+</sup> cells, comprising a majority of both these populations. Interestingly, a  
151 substantial subset of cells co-expressed *S1pr3* and the mechanically sensitive channel *Piezo2*  
152 (Fig. 3C), which is expressed in A $\beta$ , A $\delta$ , and C fibers<sup>6</sup>. The remaining *S1pr3*<sup>+</sup> cells were small  
153 diameter ( $23.4 \pm 8.2 \mu\text{m}$ ), *Trpv1*<sup>+</sup> C nociceptors (27.3% of total cells). To elucidate the role of  
154 S1PR3 in mechanical pain, we focused our analysis on A $\delta$  mechanonociceptors, as C-fibers do  
155 not contribute to baseline mechanical thresholds<sup>22</sup>.

156

157 We also used an *S1pr3*<sup>mCherry/+</sup> reporter mouse<sup>23</sup> as an independent strategy to explore *S1pr3*  
158 expression and localization. Analysis of this line detected expression of S1PR3-mCherry fusion  
159 protein in 48.3% of cultured DRG neurons (Fig. 3E), mirroring the results from ISH. Additionally,  
160 we observed S1PR3 expression in nerve fibers that innervate the skin using antibodies against  
161 mCherry in whole-mount immunohistochemistry (Fig. 3D). We observed overlap of S1PR3-  
162 expressing free nerve endings with NefH<sup>+</sup> myelinated A fibers, but did not observe expression  
163 of S1PR3 in circumferential hair follicle receptors (Fig. 3D). These results suggest that S1PR3 is  
164 not expressed in the circ-HTMR subpopulation of mechanonociceptors identified by Ghitani *et*  
165 *al.* In addition to our mRNA and protein localization experiments, calcium imaging revealed that

166 a subset of S1PR3+ neurons were activated by the Nav1.1-selective toxin Hm1a<sup>10</sup> (Fig. 3E). We  
167 conclude that a subset of *S1pr3*+ neurons represents AMs that terminate as free nerve endings.

168

### 169 **S1PR3 is required for nociceptive responses of high-threshold AM nociceptors**

170 Given that the behavioral deficit of *S1pr3*<sup>-/-</sup> animals was restricted to noxious mechanosensation,  
171 we utilized *ex vivo* skin-nerve recordings to analyze the effects of genetic ablation of S1PR3 on  
172 AM afferents, which mediate fast mechanical pain sensation (Fig. 4A). We hypothesized that  
173 S1PR3 may play a role in AM afferent function. Strikingly, the median von Frey threshold to  
174 elicit firing in AM nociceptors was significantly higher in *S1pr3*<sup>-/-</sup> animals (3.92 mN) compared to  
175 littermate controls (1.56 mN; Fig. 4C). Additionally, *S1pr3*<sup>-/-</sup> AM nociceptors displayed reduced  
176 sensitivity in their force-response relation (slope for <sup>+/-</sup> versus <sup>-/-</sup>: 50 Hz/N versus 35 Hz/N), as  
177 well as attenuated firing over the noxious, but not innocuous, range of mechanical stimulation  
178 (Fig. 4D). Furthermore, *S1pr3*<sup>-/-</sup> AM nociceptors displayed a right-shifted cumulative response  
179 curve (50% effective force for <sup>+/-</sup> versus <sup>-/-</sup>: 33.7 versus 60.0 mN; Fig. 4E), consistent with the  
180 mechanonociceptive hyposensitivity observed *in vivo*. A recent report suggested that A-  
181 nociceptors are composed of two distinct neuronal populations that differ genetically, in  
182 mechanically evoked response patterns, and in conduction velocity<sup>11</sup>. Accordingly, we found  
183 that a proportion of AM nociceptors, characterized by adapting responses to static mechanical  
184 stimuli (Adapting AM), were selectively lost in *S1pr3*<sup>-/-</sup> animals (Fig. 4F-G). However, we found  
185 no differences in conduction velocity between genotypes (Fig. 4B). We conclude that S1PR3 is  
186 an essential regulator of both mechanical threshold and sensitivity in a distinct population of AM  
187 nociceptors.

188

### 189 **S1PR3 modulates KCNQ2/3 channels to regulate AM excitability**

190 To define the molecular pathway(s) by which S1PR3 modulates mechanonociceptor function,  
191 we next examined S1P signaling in cultured DRG neurons. Unlike the environment of sensory

192 neurons in intact skin, the physiological Ringer's solutions used *in vitro* lack S1P. Thus for our *in*  
193 *vitro* experiments we tested the effects of exogenous S1P on neuronal excitability. We  
194 interrogated the molecular mechanism by which S1P signaling regulates mechanical pain using  
195 current-clamp recording of medium-diameter *S1pr3*<sup>mCherry/+</sup> dissociated DRG neurons  
196 (membrane capacitance =  $61.05 \pm 1.92$  pF), which ISH identified as putative  
197 mechanonociceptors (Fig. 3B-C). In these cells, 1  $\mu$ M S1P application did not elicit firing in the  
198 absence of current injection (Fig. 5A, Fig. S2A). However, S1P dramatically lowered the  
199 threshold to fire action potentials (rheobase) in an S1PR3-dependent manner (Fig. 5A, Fig.  
200 S2B).

201  
202 We then set out to determine how S1PR3 activity increases neuronal excitability using whole-  
203 cell voltage clamp recording. While we found that S1P application had no effect on  
204 instantaneous sodium currents or steady state potassium currents (Fig. S2C-D), S1P  
205 significantly reduced slow, voltage-dependent tail current amplitudes (Fig. 5B; Fig. 5D (top)) in  
206 an S1PR3-dependent manner (Fig. 5B, center).

207  
208 As tail currents in A $\delta$  neurons are primarily mediated by KCNQ2/3 potassium channels<sup>24</sup>, we  
209 postulated that S1P might alter tail currents through modulation of these channels. To address  
210 whether KCNQ2/3 channels mediated S1P-dependent neuronal excitability, we examined  
211 several other aspects of the S1P-sensitive current. S1P triggered a robust increase in input  
212 resistance (Fig. 5E), consistent with the closure of potassium channels. Likewise, I-V analysis  
213 revealed that the current inhibited by S1P application was carried by potassium (Fig. 5F).  
214 Additionally, the lack of an effect of S1P on resting membrane potential (Fig. S2E) and steady  
215 state potassium current (Fig. S2D) were consistent with the electrophysiological properties of  
216 KCNQ2/3 channels in DRG neurons<sup>24-27</sup>. Finally, application of the KCNQ2/3-selective inhibitor  
217 linopirdine completely occluded the effects of S1P on tail current (Fig. 5C, Fig. 5d (bottom)).



218 These findings are consistent with S1P/S1PR3-dependent inhibition of KCNQ2/3 in  
219 somatosensory neurons.

220

221 We also found that the effect of S1P on KCNQ2/3 currents was mediated by low levels of S1P,  
222 exhibiting an  $IC_{50}$  of 48 nM with saturation at 100 nM (Fig. S2F). While S1P cannot be  
223 accurately measured in non-plasma tissues, this is similar to estimated levels of S1P in  
224 peripheral tissues<sup>28,29</sup>. Thus, our *in vitro*  $IC_{50}$  supports our behavioral observations that baseline  
225 S1P levels are sufficient to maximally exert their effect on mechanical pain. In summary, our  
226 electrophysiological and behavioral observations support a model in which baseline S1P/S1PR3  
227 signaling governs mechanical pain thresholds through modulation of KCNQ2/3 channel activity  
228 in AM neurons (Fig. 6).

229

## 230 Discussion

231 This study identifies S1P/S1PR3 as a key pathway that tunes mechanical pain sensitivity.  
232 Recent studies have identified distinct populations of AM nociceptors that are required for  
233 mechanical pain<sup>11,12</sup>. Likewise, it was discovered that a subset of somatostatin-expressing  
234 spinal interneurons are required for mechanical pain transduction<sup>13</sup>. While these papers  
235 delineate the cells and circuitry of mechanical pain, the molecular underpinnings of  
236 mechanonociception in these neurons were unknown. We now demonstrate that S1PR3 is  
237 required for normal mechanosensitivity in a majority of mechanonociceptors, including the  
238 *Npy2r+* population, recently identified by Arcourt *et al.*, that innervates the epidermis and  
239 encodes noxious touch<sup>11</sup>.

240

241 While the transduction channels that detect noxious force remain enigmatic, we show that  
242 S1PR3 signaling modulates KCNQ2/3 channels to regulate excitability of mechanonociceptors

243 (Fig. 6). GPCR-mediated inhibition of KCNQ2/3 potassium channels is a well-known mechanism  
244 by which neuronal excitability is regulated<sup>30</sup>. Other studies have shown that KCNQ channels  
245 mediate excitability of A $\delta$  fibers<sup>24</sup> and that opening KCNQ2/3 channels directly with retigabine  
246 alleviates pain *in vivo*<sup>25,31,32</sup>. Our results not only complement previous work implicating  
247 KCNQ2/3 channels in pain, but also define the upstream mechanisms that promote the  
248 regulation of KCNQ2/3 channels to tune mechanical pain thresholds. Our data thus highlight  
249 S1PR3 as a novel and attractive target for the treatment of mechanical pain and describe a new  
250 signaling pathway by which S1P regulates AM nociceptor excitability.

251

252 Interestingly, the neurons that innervate the ultra-sensitive tactile organ of the star-nosed mole  
253 are highly enriched in transcripts for S1PR3 and KCNQ channels, as well as for a variety of  
254 other potassium channels<sup>14</sup>. While it is difficult to directly examine the physiological basis for  
255 heightened mechanosensitivity in the star-nosed mole, S1PR3-dependent modulation of KCNQ  
256 may represent an important mechanism underlying the high tactile sensitivity of the star organ.

257

258 Outside of the nervous system, S1P signaling via S1PR1 allows for the continuous circulation of  
259 lymphocytes between blood, lymph, and peripheral tissues<sup>33</sup>. Our findings that S1P plays a key  
260 role in somatosensation is in line with recent studies showing that sensory neurons co-opt  
261 classical immune pathways to drive chronic itch or pain<sup>34,35</sup>. What distinguishes this study from  
262 the others is that S1P signaling is critical for acute mechanical pain, even in the absence of  
263 inflammation. In the immune system, disruptions in S1P levels or S1PR1 signaling results in  
264 significant immune dysfunction and disease<sup>36-38</sup>. Paralleling the role of S1PR1 in the immune  
265 system, we propose that S1PR3 might constitutively regulate the excitability of a variety of  
266 neurons and that aberrant S1P signaling may trigger nervous system dysfunction and disease.  
267 For example, S1P has been proposed to constitutively modulate synaptic transmission and  
268 excitability of hippocampal neurons in slice recordings via S1PR3<sup>39-42</sup>, and S1PR3-deficient

269 animals display learning and memory deficits<sup>39</sup>. However, these previous studies, unlike ours,  
270 did not identify a molecular mechanism by which S1P signaling alters neuronal activity.  
271 Abnormal S1P signaling is also linked to a host of neurological disorders, including thermal  
272 hypersensitivity<sup>19</sup>, multiple sclerosis<sup>43</sup>, Huntington<sup>44</sup>, Parkinson's<sup>45</sup>, and Alzheimer's disease<sup>46</sup>.  
273 In addition to expression in the somatosensory system, S1PR3 is expressed in brain regions  
274 relevant to these disorders (Allen Brain Atlas) and may thus represent an important mechanism  
275 by which S1P signaling regulates excitability.

276

277 The relationship between lipids and ion channel activity in the context of mechanotransduction  
278 is well-established and thought to occur through direct channel-lipid interactions<sup>47,48</sup>. Here, we  
279 highlight the importance an indirect pathway in which a lipid activates a GPCR to modulate  
280 mechanoreceptor activity. Our findings complement very recent work demonstrating the diverse  
281 and complex roles that GPCRs play in somatosensory signaling<sup>49</sup>. Our study demonstrates a  
282 crucial role for S1P signaling in the peripheral nervous system and highlights the potential of  
283 S1PR3 as a target for new therapies for mechanical pain.

284

## 285 **Materials and Methods**

### 286 *Behavioral studies & mice*

287 *S1pr3<sup>mcherry/+</sup>* and *S1pr3<sup>-/-</sup>* mice were obtained from Jackson Laboratory and backcrossed to  
288 C57bl6/J. Wherever possible, wild-type/heterozygous (*S1pr3*) littermate controls were used in  
289 behavioral experiments. Mice (20–25 g) were housed in 12 h light-dark cycle at 21°C. Mice were  
290 singly housed one week prior to all behavioral experiments and were between 8-10 weeks at  
291 the time of the experiment. All mice were acclimated in behavioral chambers on 2 subsequent  
292 days for 1 hour prior to recording for itch behavior, von Frey, and radiant heat.

293

294 Itch and acute pain behavioral measurements were performed as previously described<sup>50,51</sup>. Mice  
295 were shaved one week prior to itch behavior. Compounds injected: 500  $\mu$ M TY 52156 (Tocris),  
296 50  $\mu$ M SKI II (Tocris), 10  $\mu$ M S1P (Tocris, Avanti Polar Lipids), 50 mM chloroquine (Sigma), and  
297 27 mM histamine (Tocris) in PBS with either DMSO- or Methanol-PBS vehicle controls.  
298 Pruritogens were injected using the cheek model (20  $\mu$ L) of itch, as previously described<sup>52</sup>.  
299 Behavioral scoring was performed while blind to experimental condition and mouse genotype.  
300 All scratching behavior videos were recorded for 1 hour and scored for the first 30 minutes. Bout  
301 number and length were recorded.

302

303 For radiant heat and von Frey hypersensitivity behavior, drugs were injected intradermally into  
304 the plantar surface of the hindpaw (20  $\mu$ L). Radiant heat assays were performed using the IITC  
305 Life Science Hargreaves test system. Mechanical threshold was measured using calibrated von  
306 Frey monofilaments (Touch Test) on a metal grate platform. Von Frey was performed as  
307 previously described<sup>53,54</sup> using the up-down method while blinded to compound injected and  
308 genotype. Valid responses for both von Frey and radiant heat included fast paw withdrawal,  
309 licking/biting/shaking of the affected paw, or flinching. For radiant heat and von Frey, mice were  
310 allowed to acclimate on platform for 1 hour before injection.

311

312 The pinprick assay was conducted on a von Frey testing platform (IITC). The mouse hindpaw  
313 was poked with a 31 g syringe needle without breaking the skin to induce fast acute mechanical  
314 pain. Each paw was stimulated 10 times with the needle, and the % withdrawal (fast withdrawal,  
315 licking/biting/shaking of paw, squeaking, and/or flinching) was calculated from the total number  
316 of trials.

317

318 The tape assay was conducted according to previously described methods<sup>6</sup>. Number of  
319 attempts to remove a 3 cm piece of lab tape was recorded for 10 minutes after manual tape

320 application to the rostral back. Scorer and experimenter were blinded to genotype.

321

322 For righting reflex measurements, age-matched *S1pr3*<sup>-/-</sup> and <sup>+/+</sup> P6-7 neonates were used.

323 Briefly, pups were overturned one at a time on the home cage lid while experimenter was

324 blinded to genotype. The time to righting was measured to the nearest 1/10<sup>th</sup> of a second with a

325 stopwatch.

326

327 All behavior experiments were carried out using age-matched or littermate cohorts of male mice.

328 Mice were tested in 4-part behavior chambers (IITC Life Sciences) with opaque dividers (TAP

329 Plastics) with the exception of righting reflex measurements. Itch behavior was filmed from

330 below using high-definition cameras. All experiments were performed under the policies and

331 recommendations of the International Association for the Study of Pain and approved by the

332 University of California, Berkeley Animal Care and Use Committee.

333

334 *In situ hybridization (ISH)*

335 Fresh DRG were dissected from 8-12 week old mice, flash frozen in OCT embedding medium,

336 and sectioned at 14  $\mu$ m onto slides. ISH was performed using Affymetrix Quantigene ViewISH

337 Tissue 2-plex kit according to manufacturer's instructions with Type 1 and Type 6 probes. The

338 following probes against mouse mRNAs were created by Affymetrix and used for ISH: *S1pr3*,

339 *Scn1a*, and *Piezo2*. Slides were mounted in Fluoromount with No. 1.5 coverglass. Imaging of

340 ISH experiments and all other live- and fixed-cell imaging was performed on an Olympus IX71

341 microscope with a Lambda LS-xl light source (Sutter Instruments). Images were analyzed using

342 ImageJ software. Briefly, DAPI-positive cells were circled and their fluorescence intensity (AFU)

343 for all channels was plotted against cell size using Microsoft Excel software. Co-labeling

344 analysis was performed using ImageJ. Intensity thresholds were set based on the negative

345 control (no probe) slide. Cells were defined as co-expressing if their maximum intensities

346 exceeded the threshold for both the Type 1 and Type 6 probe channels.

347

### 348 *Immunohistochemistry (IHC) of DRG*

349 8-12 week old mice were deeply anesthetized and transcardially perfused with ice-cold PBS  
350 followed by ice-cold 4% PFA. DRG were dissected and post-fixed in 4% PFA for one hour. DRG  
351 were cryo-protected overnight at 4°C in 30% sucrose-PBS, embedded in OCT, and then  
352 sectioned at 12 µm onto slides. Briefly, slides were washed 3x in PBST (0.3% Triton X-100),  
353 blocked in 2.5% horse serum + 2.5% BSA PBST, and incubated overnight at 4°C in 1:1000  
354 primary antibody in PBST + 0.5% horse serum + 0.5% BSA. Slides were washed 3X in PBS  
355 then incubated 1-2 hours at RT in 1:1000 secondary antibody. Slides were washed 3X in PBS  
356 and mounted in Fluoromount with No. 1.5 coverglass. Primary antibodies used: Rabbit anti-  
357 S1PR3, Mouse anti-NF200, Chicken anti-Peripherin (Abcam). Secondary antibodies used: Goat  
358 anti-Mouse Alexa 350, Goat anti-Chicken Alexa 547, Goat anti-Rabbit Alexa 488 (Abcam). Cells  
359 labeled with anti-peripherin were circled to define regions of interest.

360

### 361 *Whole mount skin IHC*

362 Staining was performed according to Marshall and Clary *et al*<sup>55</sup>. Briefly, 8-12 week old mice  
363 were euthanized and the back skin was shaved, depilated, and tape-stripped. The removed skin  
364 was fixed overnight in 4% PFA, then washed in PBS (3X for 10 minutes each). Dermal fat was  
365 scraped away with a scalpel and skin was washed in PBST (0.3% Triton X-100; 3X for two  
366 hours each) then incubated in 1:500 primary antibody (Rabbit anti DsRed Polyclonal antibody;  
367 Clontech #632496) in blocking buffer (PBST with 5% goat serum and 20% DMSO) for 5.5 days  
368 at 4°C. Skin was washed as before and incubated in 1:500 secondary antibody (Goat anti-  
369 Rabbit Alexa 594; Invitrogen #R37117) in blocking buffer for 3 days at 4°C. Skin was washed in  
370 PBST, serially dried in methanol: PBS solutions, incubated overnight in 100% methanol, and  
371 finally cleared with a 1:2 solution of benzyl alcohol: benzyl benzoate (BABB; Sigma) before

372 mounting.

373

#### 374 *Cell culture*

375 Cell culture was carried out as previously described<sup>17</sup>. Briefly, neurons from dorsal root ganglia  
376 (2-8 week old adults) or trigeminal ganglia (P0) were dissected and incubated for 10 min in 1.4  
377 mg ml<sup>-1</sup> Collagenase P (Roche) in Hanks calcium-free balanced salt solution, followed by  
378 incubation in 0.25% standard trypsin (vol/vol) STV versene-EDTA solution for 2 min with gentle  
379 agitation. Cells were then triturated, plated onto Poly D-Lysine coated glass coverslips and used  
380 within 20 h. Media: MEM Eagle's with Earle's BSS medium, supplemented with 10% horse  
381 serum (vol/vol), MEM vitamins, penicillin/streptomycin and L-glutamine.

382

#### 383 *Calcium imaging*

384 Ca<sup>2+</sup> imaging experiments were carried out as previously described<sup>17</sup>. Cells were loaded for 60  
385 min at room temperature with 10 μM Fura-2AM supplemented with 0.01% Pluronic F-127  
386 (wt/vol, Life Technologies) in a physiological Ringer's solution containing (in mM) 140 NaCl, 5  
387 KCl, 10 HEPES, 2 CaCl<sub>2</sub>, 2 MgCl<sub>2</sub> and 10 D-(+)-glucose, pH 7.4. All chemicals were purchased  
388 from Sigma. Acquired images were displayed as the ratio of 340 nm/ 380 nm. Cells were  
389 identified as neurons by eliciting depolarization with high potassium Ringer's solution (75 mM) at  
390 the end of each experiment. Responding neurons were defined as those having a > 15%  
391 increase from baseline ratio. Image analysis and statistics were performed using automated  
392 routines in Igor Pro (WaveMetrics). Fura-2 ratios were normalized to the baseline ratio  
393  $F_{340}/F_{380} = (\text{Ratio})/(\text{Ratio } t = 0)$ .

394

#### 395 *Ex vivo skin-nerve electrophysiology*

396 Touch-evoked responses in the skin were recorded after dissecting the hind limb skin and  
397 saphenous nerve from 7-10 week old mice, according to published methods<sup>56,57</sup>. The skin was

398 placed epidermis-side-up in a custom chamber and perfused with carbogen-buffered synthetic  
399 interstitial fluid (SIF) kept at 32 °C with a temperature controller (model TC-344B, Warner  
400 Instruments). The nerve was kept in mineral oil in a recording chamber, teased apart, and  
401 placed onto a gold recording electrode connected with a reference electrode to a differential  
402 amplifier (model 1800, A-M Systems). The extracellular signal was digitized using a PowerLab  
403 8/35 board (AD Instruments) and recorded using LabChart software (AD Instruments).

404

405 For these studies, we focused on A-mechanoreceptors (AMs). To identify responses from  
406 these afferents in mutant and control genotypes, we used a mechanical search paradigm with a  
407 fine glass probe. Afferents were classified as AMs according to the following criteria: (1) A $\delta$   
408 conduction velocity (approximately, 1 to ( $\leq 12$  m/s<sup>-1</sup>), (2) medium-sized receptive fields, (3)  
409 sustained response to mechanical indentation<sup>9,57,58</sup>.

410

411 Touch-sensitive afferents that did not meet these criteria were not analyzed further. Responses  
412 were classified as Adapting AMs if the ratio of mean firing rate in the dynamic phase of  
413 stimulation (first 0.2 s) to the static phase of stimulation (last 4.8 s) was greater than 2, and Non-  
414 Adapting AMs if the ratio was less than or equal to 2. Non-responders (Fig. 4g) responded to  
415 suprathreshold mechanical stimulation with von Frey monofilaments (tip diameter <0.5 mm), but  
416 not to maximal controlled mechanical stimulation (256 mN, tip diameter 2 mm). All recordings  
417 and analyses were performed blind to genotype.

418

419 Mechanical responses were elicited with von Frey monofilaments and a force controlled custom-  
420 built mechanical stimulator. Mechanical thresholds were defined as the lowest von Frey  
421 monofilament to reliably elicit at least one action potential. Force controlled mechanical stimuli  
422 were delivered using a computer controlled, closed-loop, mechanical stimulator (Model 300C-I,  
423 Aurora Scientific, 2 mm tip diameter). Low-pass filtered, 5-second long, length control steps



424 (square wave) simultaneously delivered with permissive force control steps (square wave) were  
425 generated using LabChart software (AD Instruments). An arbitrarily selected force step-and-hold  
426 protocol (8, 32, 4, 64, 128, 16, 256 mN) was delivered to all fibers. The period between  
427 successive displacements was 60 seconds.

428

429 Conduction velocity was measured by electrically stimulating identified receptive fields. Spike  
430 sorting by principal component analysis (PCA) and density based clustering, and data analysis  
431 was performed off-line with custom-made software in MATLAB. Statistics were performed in  
432 Prism.

433

#### 434 *In vitro electrophysiology*

435 Electrophysiological experiments were carried out as previously described<sup>17</sup>. Briefly, recordings  
436 were collected at 5 kHz and filtered at 2 kHz (Axopatch 200B, pClamp software). Electrode  
437 resistance ranged between 1.5–5 M $\Omega$ . Internal solution contained 140 mM KCl, 2 mM MgCl<sub>2</sub>, 1  
438 mM EGTA, 5 mM HEPES, 1 mM Na<sub>2</sub>ATP, 100  $\mu$ M GTP, and 100  $\mu$ M cAMP (pH 7.4). Bath  
439 solution was physiological Ringer's solution. The pipette potential was canceled before seal  
440 formation. Cell capacitance was canceled before whole cell voltage-clamp recordings.  
441 Experiments were carried out only on cells with a series resistance of less than 30 M $\Omega$ . Analysis  
442 of electrophysiology data was performed in pClamp and IgorPro.

443

#### 444 *Statistical analyses*

445 All statistical analyses, except for skin nerve data (see above), were performed using IgorPro  
446 software or Microsoft Excel. Values are reported as the mean  $\pm$  SEOM where multiple  
447 independent experiments are pooled and reported (for whole cell electrophysiology), and mean  
448  $\pm$  SD where one experiment was performed with multiple wells (for calcium imaging) or mice (for  
449 behavior). For comparison between two groups, Student's unpaired 2-tailed t-test was used. A

450 paired t-test was employed only for measurements within the same biological replicate and after  
451 a given treatment. For single-point comparison between >2 groups, a one-way ANOVA followed  
452 by Tukey Kramer post hoc test was used. For the time course comparison between 2 groups, 2-  
453 way ANOVA was used and single comparison p-values were derived using Tukey's HSD. For  
454 comparing distributions, a type II Kolmogorov-Smirnov test was used. Number of mice or  
455 samples required to attain significance was not calculated beforehand, and where multiple  
456 statistical tests were performed, a Bonferroni correction was applied. In figure legends,  
457 significance was labeled as: n.s., not significant,  $p \geq 0.05$ ; \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ .

458

## 459 Author Contributions

460 R.Z.H, D.M.B., and R.B. conceived experiments and wrote the manuscript. R.Z.H. performed  
461 behavioral, immunostaining, whole cell electrophysiology, calcium imaging, and ISH, and  
462 analyzed data and made figures. T.M. also performed ISH experiments. E. A. L. & B.H.  
463 conceived and analyzed *ex vivo* recordings. B.U.H. and S. C. performed *ex vivo* recordings. All  
464 authors contributed to the final version of the manuscript.

465

## 466 Acknowledgements

467 We thank Z. Rifi (UC Berkeley) for assistance with scoring itch behavior, R. P. Dalton (UC  
468 Berkeley) for assistance with confocal microscopy, and P. Lishko and M. Miller (UC Berkeley)  
469 for advice regarding lipid stability and usage. We would also like to thank R. Clary (Columbia)  
470 for whole mount skin staining protocols and D. Julius (UC San Francisco) for the gift of Hm1a  
471 spider toxin. We are grateful to all members of the D.M.B Laboratory (UC Berkeley) for  
472 constructive feedback and criticism. The National Institutes of Health grants NS077224 (to  
473 D.M.B and R.B.), AR059385 (to D.M.B.), AR051219 (to E.A.L), NS105449 and GM007367 (to  
474 B.U.H), and NS063307 (to the Neurobiology Course at the Marine Biological Laboratory); and a

475 Howard Hughes Medical Institute Faculty Scholars grant (to D.M.B) supported this work.

## 476 Competing interests

477 The authors declare no competing interests at this time.

478

## 479 References

- 480 1. Caterina, M. J., Schumacher, M. a, Tominaga, M., Rosen, T. a, Levine, J. D. & Julius, D.  
481 The capsaicin receptor: a heat-activated ion channel in the pain pathway. *Nature* **389**,  
482 816–824 (1997).
- 483 2. Caterina, M. J, Leffler. A., Malmberg, A. B., Martin, W. J., Trafton, J., Petersen-Zeit, K.  
484 R., Koltzenburg, M., Basbaum, A. I., Julius, J. D. Impaired Nociception and Pain  
485 Sensation in Mice Lacking the Capsaicin Receptor. *Science* **288**, 306–313 (2000).
- 486 3. McKemy, D. D., Neuhausser, W. M. & Julius, D. Identification of a cold receptor reveals a  
487 general role for TRP channels in thermosensation. *Nature* **416**, 52–58 (2002).
- 488 4. Bautista, D. M., Siemens, J., Glazer, J. M., Tsuruda, P. R., Basbaum, A. I., Stucky, C. L.,  
489 Jordt, S.-E. & Julius, D. The menthol receptor TRPM8 is the principal detector of  
490 environmental cold. *Nature* **448**, 204–208 (2007).
- 491 5. Coste, B., Mathur, J., Schmidt, M., Earley, T. J., Ranade, S., Petrus, M. J., Dubin, A. E. &  
492 Patapoutian, A. Piezo1 and Piezo2 Are Essential Components of Distinct Mechanically  
493 Activated Cation Channels. *Science* **330**, 55–60 (2010).
- 494 6. Ranade, S. S., Woo, S., Dubin, A. E., Moshourab, R. a, Wetzel, C., Petrus, M., Mathur,  
495 J., Bégay, V., Coste, B., Mainquist, J., Wilson, a J., Francisco, A. G., Reddy, K., Qiu, Z.,  
496 Wood, N., Lewin, G. R. & Patapoutian, A. Piezo2 is the major transducer of mechanical  
497 forces for touch sensation in mice. *Nature* **516**, 121–125 (2014).
- 498 7. Woo, S.-H., Ranade, S., Weyer, A. D., Dubin, A. E., Baba, Y., Qiu, Z., Petrus, M.,  
499 Miyamoto, T., Reddy, K., Lumpkin, E. a., Stucky, C. L. & Patapoutian, A. Piezo2 is  
500 required for Merkel-cell mechanotransduction. *Nature* **509**, 622–626 (2014).

- 501 8. Basbaum, A. I., Bautista, D. M., Scherrer, G. & Julius, D. Cellular and Molecular  
502 Mechanisms of Pain. *Cell* **139**, 267–284 (2009).
- 503 9. Koltzenburg, M., Stucky, C. L., Lewin, G. R., Bautista, M., Lechner, S. G., Gemes, G.,  
504 Koopmeiners, A., Rigaud, M., Lirk, P., Sapunar, D., Latha, M., Vilceanu, D., Garrison, S.  
505 R., Ljubkovic, M., Mueller, S. J., Cheryl, L. & Hogan, Q. H. Receptive Properties of Mouse  
506 Sensory Neurons Innervating Hairy Skin Receptive Properties of Mouse Sensory  
507 Neurons Innervating Hairy Skin. *J. Neurophysiol.* **78**, 1841–1850 (1997).
- 508 10. Osteen, J. D., Herzig, V., Gilchrist, J., Emrick, J. J., Zhang, C., Wang, X., Castro, J.,  
509 Garcia-Caraballo, S., Grundy, L., Rychkov, G. Y., Weyer, A. D., Dekan, Z., Undheim, E.  
510 A. B., Alewood, P., Stucky, C. L., Brierley, S. M., Basbaum, A. I., Bosmans, F., King, G.  
511 F. & Julius, D. Selective spider toxins reveal a role for the Nav1.1 channel in mechanical  
512 pain. *Nature* **534**, 494–9 (2016).
- 513 11. Arcourt, A., Gorham, L., Dhandapani, R., Prato, V., Taberner, F. J., Wende, H.,  
514 Gangadharan, V., Birchmeier, C., Heppenstall, P. A. & Lechner, S. G. Touch Receptor-  
515 Derived Sensory Information Alleviates Acute Pain Signaling and Fine-Tunes Nociceptive  
516 Reflex Coordination. *Neuron* **93**, 179–193 (2017).
- 517 12. Ghitani, N., Barik, A., Szczot, M., Thompson, J. H., Li, C., Le Pichon, C. E., Krashes, M.  
518 J. & Chesler, A. T. Specialized Mechanosensory Nociceptors Mediating Rapid  
519 Responses to Hair Pull. *Neuron* **95**, 944–954.e4 (2017).
- 520 13. Duan, B., Cheng, L., Bourane, S., Britz, O., Padilla, C., Garcia-campmany, L., Krashes,  
521 M., Knowlton, W., Velasquez, T., Ren, X., Ross, S. E., Lowell, B. B., Wang, Y., Goulding,  
522 M. & Ma, Q. Identification of Spinal Circuits Transmitting and Gating Mechanical Pain.  
523 *Cell* **159**, 1417–1432 (2014).
- 524 14. Gerhold, K. a., Pellegrino, M., Tsunozaki, M., Morita, T., Leitch, D. B., Tsuruda, P. R.,  
525 Brem, R. B., Catania, K. C. & Bautista, D. M. The Star-Nosed Mole Reveals Clues to the  
526 Molecular Basis of Mammalian Touch. *PLoS One* **8**, (2013).

- 527 15. Usoskin, D., Furlan, A., Islam, S., Abdo, H., Lönnerberg, P., Lou, D., Hjerling-Leffler, J.,  
528 Haeggström, J., Kharchenko, O., Kharchenko, P. V, Linnarsson, S. & Ernfors, P.  
529 Unbiased classification of sensory neuron types by large-scale single-cell RNA  
530 sequencing. *Nat. Neurosci.* **18**, 145–153 (2015).
- 531 16. Kono, M., Mi, Y., Liu, Y., Sasaki, T., Allende, M. L., Wu, Y. P., Yamashita, T. & Proia, R.  
532 L. The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately  
533 during embryonic angiogenesis. *J. Biol. Chem.* **279**, 29367–29373 (2004).
- 534 17. Wilson, S. R., Gerhold, K. a, Bifolck-Fisher, A., Liu, Q., Patel, K. N., Dong, X. & Bautista,  
535 D. M. TRPA1 is required for histamine-independent, Mas-related G protein-coupled  
536 receptor-mediated itch. *Nat. Neurosci.* **14**, 595–602 (2011).
- 537 18. Chiba, Y., Takeuchi, H., Sakai, H. & Misawa, M. SKI-II, an inhibitor of sphingosine kinase,  
538 ameliorates antigen-induced bronchial smooth muscle hyperresponsiveness, but not  
539 airway inflammation, in mice. *J. Pharmacol. Sci.* **114**, 304–310 (2010).
- 540 19. Mair, N., Benetti, C., Andratsch, M., Leitner, M. G., Constantin, C. E., Camprubí-Robles,  
541 M., Quarta, S., Biasio, W., Kuner, R., Gibbins, I. L., Kress, M. & Haberberger, R. V.  
542 Genetic evidence for involvement of neuronally expressed s1P1 receptor in nociceptor  
543 sensitization and inflammatory pain. *PLoS One* **6**, (2011).
- 544 20. Shaner, R. L., Allegood, J. C., Park, H., Wang, E., Kelly, S., Haynes, C. a, Sullards, M. C.  
545 & Merrill, A. H. Quantitative analysis of sphingolipids for lipidomics using triple quadrupole  
546 and quadrupole linear ion trap mass spectrometers. *J. Lipid Res.* **50**, 1692–1707 (2009).
- 547 21. Camprubi-Robles, M., Mair, N., Andratsch, M., Benetti, C., Beroukas, D., Rukwied, R.,  
548 Langeslag, M., Proia, R. L., Schmelz, M., Ferrer Montiel, A. V, Haberberger, R. V, Kress,  
549 M. & Camprubí-Robles, M. Sphingosine-1-phosphate-induced nociceptor excitation and  
550 ongoing pain behavior in mice and humans is largely mediated by S1P3 receptor. *J.*  
551 *Neurosci.* **33**, 2582–2592 (2013).
- 552 22. Abrahamsen, B., Zhao, J., Asante, C. O., Cendan, C. M., Marsh, S., Martinez-Barbera, J.

- 553 P., Nassar, M. A., Dickenson, A. H. & Wood, J. N. The Cell and Molecular Basis of  
554 Mechanical, Cold, and Inflammatory Pain. *Science* **321**, 702 (2008).
- 555 23. Sanna, M. G., Vincent, K. P., Repetto, E., Nhan, N., Brown, S. J., Abgaryan, L., Riley, S.  
556 W., Leaf, N. B., Cahalan, S. M., Kiosses, W. B., Kohno, Y., Heller Brown, J., McCulloch,  
557 A. D., Rosen, H. & Gonzalez-Cabrera, P. J. Bitopic S1P3 Antagonist Rescue from  
558 Complete Heart Block: Pharmacological and Genetic Evidence for Direct S1P3  
559 Regulation of Mouse Cardiac Conduction. *Mol. Pharmacol.* **89**, 176–186 (2015).
- 560 24. Schu, S., Orozco, I. J. & Jentsch, T. J. KCNQ Potassium Channels Modulate Sensitivity  
561 of Skin Down hair (D-hair) Mechanoreceptors. *J. Biol. Chem.* **291**, 5566–5575 (2016).
- 562 25. Zheng, Q., Fang, D., Liu, M., Cai, J., Wan, Y., Han, J. S. & Xing, G. G. Suppression of  
563 KCNQ/M (Kv7) potassium channels in dorsal root ganglion neurons contributes to the  
564 development of bone cancer pain in a rat model. *Pain* **154**, 434–448 (2013).
- 565 26. Crozier, R. A., Ajit, S. K., Kaftan, E. J. & Pausch, M. H. MrgD Activation Inhibits KCNQ /  
566 M-Currents and Contributes to Enhanced Neuronal Excitability. *J. Neurosci.* **27**, 4492–  
567 4496 (2007).
- 568 27. Heidenreich, M., Lechner, S. G., Vardanyan, V., Wetzel, C., Cremers, C. W., De  
569 Leenheer, E. M., Aránguez, G., Moreno-Pelayo, M. Á., Jentsch, T. J. & Lewin, G. R.  
570 KCNQ4 K(+) channels tune mechanoreceptors for normal touch sensation in mouse and  
571 man. *Nat. Neurosci.* **15**, 138–145 (2012).
- 572 28. Bäumer, W., Rossbach, K., Mischke, R., Reines, I., Langbein-Detsch, I., Lüth, A. &  
573 Kleuser, B. Decreased concentration and enhanced metabolism of sphingosine-1-  
574 phosphate in lesional skin of dogs with atopic dermatitis: disturbed sphingosine-1-  
575 phosphate homeostasis in atopic dermatitis. *J. Invest. Dermatol.* **131**, 266–268 (2011).
- 576 29. Ramos-Perez, W. D., Fang, V., Escalante-Alcalde, D., Cammer, M. & Schwab, S. R. A  
577 map of the distribution of sphingosine 1-phosphate in the spleen. *Nat. Immunol.* **16**,  
578 1245–52 (2015).


- 579 30. Suh, B.-C., Inoue, T., Meyer, T. & Hille, B. Rapid Chemically Induced Changes of  
580 PtdIns(4,5)P<sub>2</sub> Gate KCNQ Ion Channels. *Science* **314**, 1454–1457 (2006).
- 581 31. Blackburn-Munro, G. & Jensen, B. S. The anticonvulsant retigabine attenuates  
582 nociceptive behaviours in rat models of persistent and neuropathic pain. *Eur. J.*  
583 *Pharmacol.* **460**, 109–116 (2003).
- 584 32. Hayashi, H., Iwata, M., Tsuchimori, N. & Matsumoto, T. Activation of peripheral KCNQ  
585 channels attenuates inflammatory pain. *Mol. Pain* **10**, 15 (2014).
- 586 33. Matloubian, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende,  
587 M. L., Proia, R. L. & Cyster, J. G. Lymphocyte egress from thymus and peripheral  
588 lymphoid organs is dependent on S1P receptor 1. *Nature* **427**, 355–360 (2004).
- 589 34. Pinho-Ribeiro, F. A., Verri, W. A. & Chiu, I. M. Nociceptor Sensory Neuron–Immune  
590 Interactions in Pain and Inflammation. *Trends Immunol.* **38**, 5–19 (2017).
- 591 35. Oetjen, L. K., Mack, M. R., Feng, J., Whelan, T. M., Niu, H., Guo, C. J., Chen, S., Trier, A.  
592 M., Xu, A. Z., Tripathi, S. V., Luo, J., Gao, X., Yang, L., Hamilton, S. L., Wang, P. L.,  
593 Brestoff, J. R., Council, M. L., Brasington, R., Schaffer, A., Brombacher, F., Hsieh, C.-S.,  
594 Gereau, R. W., Miller, M. J., Chen, Z.-F., Hu, H., Davidson, S., Liu, Q. & Kim, B. S.  
595 Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch.  
596 *Cell* **129**, 742–751 (2017).
- 597 36. Donoviel, M. S., Hait, N. C., Ramachandran, S., Maceyka, M., Takabe, K., Milstien, S.,  
598 Oravec, T. & Spiegel, S. Spinster 2, a sphingosine 1-phosphate transporter, plays a  
599 Critical Role in inflammatory and Autoimmune Diseases. *FASEB J.* **29**, 5018–5028  
600 (2015).
- 601 37. Schwab, S. R., Pereira, J. P., Matloubian, M., Xu, Y., Huang, Y. & Cyster, J. G.  
602 Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients.  
603 *Science* **309**, 1735–1739 (2005).
- 604 38. Allende, M. L., Bektas, M., Lee, B. G., Bonifacino, E., Kang, J., Tuymetova, G., Chen, W.,

- 605 Saba, J. D. & Proia, R. L. Sphingosine-1-phosphate lyase deficiency produces a pro-  
606 inflammatory response while impairing neutrophil trafficking. *J. Biol. Chem.* **286**, 7348–  
607 7358 (2011).
- 608 39. Weth-Malsch, D., Langeslag, M., Beroukas, D., Zangrandi, L., Kastenberger, I., Quarta,  
609 S., Malsch, P., Kalpachidou, T., Schwarzer, C., Proia, R. L., Haberberger, R. V. & Kress,  
610 M. Ablation of Sphingosine 1-Phosphate Receptor Subtype 3 Impairs Hippocampal  
611 Neuron Excitability In vitro and Spatial Working Memory In vivo. *Front. Cell. Neurosci.* **10**,  
612 1–12 (2016).
- 613 40. Mitroi, D. N., Deutschmann, A. U., Raucamp, M., Karunakaran, I., Glebov, K., Hans, M.,  
614 Walter, J., Saba, J., Gräler, M., Ehninger, D., Sopova, E., Shupliakov, O., Swandulla, D.  
615 & van Echten-Deckert, G. Sphingosine 1-phosphate lyase ablation disrupts presynaptic  
616 architecture and function via an ubiquitin- proteasome mediated mechanism. *Sci. Rep.* **6**,  
617 37064 (2016).
- 618 41. Chan, J. P. & Sieburth, D. Localized Sphingolipid Signaling at Presynaptic Terminals Is  
619 Regulated by Calcium Influx and Promotes Recruitment of Priming Factors. *J. Neurosci.*  
620 **32**, 17909–17920 (2012).
- 621 42. Riganti, L., Antonucci, F., Gabrielli, M., Prada, I., Giussani, P., Viani, P., Valtorta, F.,  
622 Menna, E., Matteoli, M. & Verderio, C. Sphingosine-1-Phosphate (S1P) Impacts  
623 Presynaptic Functions by Regulating Synapsin I Localization in the Presynaptic  
624 Compartment. *J. Neurosci.* **36**, 4624–4634 (2016).
- 625 43. Choi, J. W., Gardell, S. E., Herr, D. R., Rivera, R., Lee, C.-W., Noguchi, K., Teo, S. T.,  
626 Yung, Y. C., Lu, M., Kennedy, G. & Chun, J. FTY720 (fingolimod) efficacy in an animal  
627 model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1)  
628 modulation. *Proc. Natl. Acad. Sci. U. S. A.* **108**, 751–6 (2011).
- 629 44. Di Pardo, A., Amico, E., Favellato, M., Castrataro, R., Fucile, S., Squitieri, F. & Maglione,  
630 V. FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and




- 631 mouse models of huntington disease. *Hum. Mol. Genet.* **23**, 2251–2265 (2014).
- 632 45. Zhao, P., Yang, X., Yang, L., Li, M., Wood, K., Liu, Q. & Zhu, X. Neuroprotective effects  
633 of fingolimod in mouse models of Parkinson’s disease. *FASEB J.* **31**, 172–179 (2017).
- 634 46. Couttas, T. a, Kain, N., Daniels, B., Lim, X. Y., Shepherd, C., Kril, J., Pickford, R., Li, H.,  
635 Garner, B. & Don, A. S. Loss of the neuroprotective factor Sphingosine 1-phosphate early  
636 in Alzheimer’s disease pathogenesis. *Acta Neuropathol. Commun.* **2**, 9 (2014).
- 637 47. Nomura, T., Cranfield, C. G., Deplazes, E., Owen, D. M., Macmillan, a., Battle, a. R.,  
638 Constantine, M., Sokabe, M. & Martinac, B. Differential effects of lipids and lyso-lipids on  
639 the mechanosensitivity of the mechanosensitive channels MscL and MscS. *Proc. Natl.*  
640 *Acad. Sci.* **109**, 8770–8775 (2012).
- 641 48. Brohawn, S. G., Su, Z. & MacKinnon, R. Mechanosensitivity is mediated directly by the  
642 lipid membrane in TRAAK and TREK1 K<sup>+</sup> channels. *Proc. Natl. Acad. Sci. U. S. A.* **111**,  
643 3614–9 (2014).
- 644 49. Scholz, N., Guan, C., Nieberler, M., Grotemeyer, A., Maiellaro, I., Gao, S., Beck, S.,  
645 Pawlak, M., Sauer, M., Asan, E., Rothmund, S., Winkler, J., Prömel, S., Nagel, G.,  
646 Langenhan, T. & Kittel, R. J. Mechano-dependent signaling by Latrophilin/CIRL quenches  
647 cAMP in proprioceptive neurons. *Elife* **6**, 1–21 (2017).
- 648 50. Morita, T., McClain, S. P., Batia, L. M., Pellegrino, M., Wilson, S. R., Kienzler, M. A.,  
649 Lyman, K., Olsen, A. S. B., Wong, J. F., Stucky, C. L., Brem, R. B. & Bautista, D. M.  
650 HTR7 Mediates Serotonergic Acute and Chronic Itch. *Neuron* **87**, 124–138 (2015).
- 651 51. Tsunozaki, M., Lennertz, R. C., Vilceanu, D., Katta, S., Stucky, C. L. & Bautista, D. M. A  
652 ‘toothache tree’ alkylamide inhibits A $\delta$  mechanonociceptors to alleviate mechanical pain.  
653 *J. Physiol.* **591**, 3325–40 (2013).
- 654 52. Shimada, S. G. & LaMotte, R. H. Behavioral differentiation between itch and pain in  
655 mouse. *Pain* **139**, 681–687 (2008).
- 656 53. Dixon, W. J. The Up-and-Down Method for Small Samples. *J. Am. Stat. Assoc.* **60**, 967–


- 657 978 (1980).
- 658 54. Chaplan, SR, Bach, FW, Pogrel, JW, Chung, JM, Yaksh, T. Quantitative assessment of  
659 tactile allodynia evoked by unilateral ligation of the fifth and sixth lumbar nerves in the rat.  
660 *J. Neurosci.* **53**, 55–63 (1994).
- 661 55. Marshall, K. L., Clary, R. C., Baba, Y., Orlowsky, R. L., Gerling, G. J. & Lumpkin, E. A.  
662 Touch Receptors Undergo Rapid Remodeling in Healthy Skin. *Cell Rep.* **17**, 1719–1727  
663 (2016).
- 664 56. Maksimovic, S., Nakatani, M., Baba, Y., Nelson, A. M., Marshall, K. L., Wellnitz, S. A.,  
665 Firozi, P., Woo, S.-H., Ranade, S., Patapoutian, A. & Lumpkin, E. A. Epidermal Merkel  
666 cells are mechanosensory cells that tune mammalian touch receptors. *Nature* **509**, 617–  
667 621 (2014).
- 668 57. Wellnitz, S. A., Lesniak, D. R., Gerling, G. J. & Lumpkin, E. A. The Regularity of  
669 Sustained Firing Reveals Two Populations of Slowly Adapting Touch Receptors in Mouse  
670 Hairy Skin. *J. Neurophysiol.* **103**, 3378–3388 (2010).
- 671 58. Zimmermann, K., Hein, A., Hager, U., Kaczmarek, J. S., Turnquist, B. P., Clapham, D. E.  
672 & Reeh, P. W. Phenotyping sensory nerve endings in vitro in the mouse. *Nat. Protoc.* **4**,  
673 (2009).
- 674




**Figure 1. S1PR3 mediates acute mechanical pain.** A. von Frey 50% withdrawal threshold measurements for *S1pr3*<sup>+/+</sup> (WT, N = 8), <sup>+/-</sup> (HET, N = 7) and <sup>-/-</sup> (KO, N = 12) mice.  $p < 0.0001$  (one-way ANOVA). Tukey Kramer post hoc comparisons for KO and HET to WT indicated on graph. B. von Frey force-response graph for WT (N = 8) versus KO (N = 12) animals;  $p_{\text{genotype}} < 0.0001$  (two-way ANOVA). Tukey HSD comparisons between genotypes are indicated for given forces. C. % withdrawal to pinprick stimulation of hindpaw for HET versus KO animals;  $p < 0.0001$  (unpaired t-test; N = 5-7 mice per group). D. Number of attempted removal bouts in tape assay for WT (N = 2), HET (N = 2), and KO (N = 5) mice;  $p = 0.172$  (one-way ANOVA). E. von Frey 50% withdrawal threshold measurements for mice pre- and post-injection of 500  $\mu\text{M}$  TY 52156 (N = 10), 10  $\mu\text{M}$  W146 (N = 6), or 1% DMSO-PBS vehicle (N = 17);  $p = 0.016, 0.650$  (two-tailed paired t-test comparing vehicle- vs. drug-injected paw). F. von Frey force-response graph for mice injected with either 1% DMSO-PBS or 500  $\mu\text{M}$  TY 52156;  $p_{\text{treatment}} < 1\text{e-}05$  (two-way ANOVA; N = 4 mice per group). Tukey HSD comparisons were made between treatment groups and significant differences at a given force are indicated on graph. Unless otherwise indicated, error bars represent mean  $\pm$  SD. See Source Data Table 1 for additional details.




**Figure 2. Endogenous S1P mediates acute mechanical pain.** A. von Frey 50% withdrawal measurements for mice pre- and post-injection of 50  $\mu$ M SKI II (N = 8) or 10  $\mu$ M S1P (N = 7);  $p = 0.003, 0.604$  (two-tailed paired t-test). B. von Frey force-response graph for animals injected with 10  $\mu$ M S1P or 0.1% MeOH-PBS;  $p_{genotype} > 0.05$  (two-way ANOVA; N = 8 mice per group). No Tukey HSD comparisons at any force between genotypes were significant. Error bars represent mean  $\pm$  SD. See Source Data Table 2 for additional details.



**Figure 3. S1PR3 is expressed in A mechanonociceptors.** A. ISH of *S1pr3* (green) in sectioned DRG from adult wild-type (top) and S1PR3 KO (bottom) mice (20x air objective; scale = 50  $\mu$ m). B. Representative Co-ISH of *S1pr3* (green; left) with *Scn1a*, *Npy2r*, and *Piezo2* (magenta; center). Right column: overlay with co-localized regions colored white (10x air objective; scale = 100  $\mu$ m). C. Bar chart showing the % of total cells expressing the indicated marker (grey) and the % of total cells co-expressing both marker and *S1pr3* (green) from the images in Fig. 3B. D. Whole-mount skin immunohistochemistry with anti-DsRed antibody (green) and anti-NefH antibody (magenta) in an *S1pr3*<sup>mCherry/+</sup> animal (20x water objective; scale = 50  $\mu$ m). Arrows indicate S1PR3<sup>+</sup> epidermal fibers (left image) or S1PR3<sup>-</sup> circumferential fibers (right image). E. Quantification of % of total cells expressing *S1pr3* from DRG ISH and mCherry from dissociated DRG cultures (N = 2 animals each experiment). F. (Left) Fura-2 AM calcium imaging before (left) and after (center) addition of 500 nM Hm1a in *S1pr3*<sup>mCherry/+</sup> P0 TG neurons. Right-hand image indicates mCherry fluorescence. Arrows indicate one mCherry<sup>+</sup>/Hm1a-responsive cell. (Right) % of Hm1a-responsive P0 TG neurons that are mCherry<sup>+</sup> (N = 1 animal, 1230 total neurons).




**Figure 4. S1PR3 is required for nociceptive responses of high-threshold AM nociceptors.** A. Representative traces of AM fiber activity over time in *ex vivo* skin-saphenous nerve recording in response to stimulation (128 mN, top) from S1PR3<sup>+/-</sup> (HET) (middle) and <sup>-/-</sup> (KO) (bottom) mice. B. Conduction velocity (CV) of AM fibers in S1PR3 HET and KO mice.  $p = 0.65$  (two-tailed t-test); N = 40, 36 fibers; errors, mean  $\pm$  SEM. C. von Frey threshold of AM fibers in S1PR3 HET and KO skin. \*\*\* $p < 0.0001$  (Mann-Whitney test); lines, median; boxes, 25-75 percentile; whiskers, min-max. D. Mean firing rate of AM fibers in response to force controlled stimulation (4, 8, 16, 32, 64, 128, 256 mN). \*\* $p = 0.001$ , \*\*\* $p = 0.0002$  (two-way ANOVA, Sidak's post-hoc); lines, linear regression (HET: slope, 50 Hz/N,  $R^2$ , 0.99; KO: slope, 35 Hz/N,  $R^2$ , 0.95). E. Cumulative response plot of AM fibers to force controlled stimulation (solid lines); four-parameter logistic fit from which half-maximal force was estimated for each genotype (dotted lines). F. Representative traces of Non-Adapting and Adapting AMs in response to force controlled stimulation (256 mN, top) for S1PR3 HET and KO mice; blue regions, dynamic phase of stimulation. G. Proportion of fibers classified by pattern of mechanically evoked responses to 256 mN of stimulation: Non-Responder (HET, 2/40 fibers; KO 5/36), Non-Adapting AM (HET, 18/40; KO, 29/36), Adapting AM (HET, 20/40; KO, 2/36). Non-Responders fired action potentials to large magnitude von Frey monofilaments (<0.5 mm tip diameter), but not to 256 mN of controlled mechanical stimulation (2 mm tip diameter). Classification of Non-Adapting vs. Adapting AMs detailed in methods. \*\*\* $p < 0.00001$  (Chi-square test). See Source Data Table 4 for additional details.




**Figure 5. S1PR3 modulates KCNQ2/3 channels to regulate AM excitability.** All experiments were performed in *S1pr3*<sup>mCherry/+</sup> or <sup>-/-</sup> DRG neurons. A. (Left) Example traces of a single mCherry+ neuron in whole cell current clamp before and after S1P application. (Right) % change in rheobase after S1P application for *S1pr3*<sup>mCherry/+</sup> (left) and KO (right) neurons ( $p_{WT,KO} = 0.012, 0.287$ ; two-tailed paired t-test; N = 7, 12 cells). B. %  $\Delta$  in tail current after S1P or 1% DMSO vehicle application for *S1pr3*<sup>mCherry/+</sup> and KO medium-diameter neurons ( $p = 0.014$ ; one-way ANOVA; N = 10, 13, 10 cells). Tukey Kramer post hoc  $p$ -values indicated on graph. C. %  $\Delta$  in tail current after indicated treatments (LINO = 100  $\mu$ M linopirdine) for *S1pr3*<sup>mCherry/+</sup> medium-diameter neurons; ( $p = 0.47$ ; two-tailed paired t-test; N = 12 cells). D. (Top) Averaged tail current traces of a single mCherry+ neuron in whole cell voltage clamp recording pre- and post-S1P. (Bottom) Averaged tail current traces of a single mCherry+ neuron in whole cell voltage clamp recording with indicated treatment. E. %  $\Delta$  in input resistance after S1P or vehicle application ( $p = 0.017$ ; two-tailed paired t-test; N = 4 cells per group). F. Instantaneous current-voltage relationship after subtraction of the post-S1P current from the pre-S1P current. Current reverses at -60.125 mV; N = 6 cells. Data were fitted with a Boltzmann equation. A pre-pulse stimulation of +100 mV for 100 ms was used. Unless indicated otherwise, all error bars represent mean  $\pm$  SEOM. See Source Data Table 5 for additional details.

## In AM nociceptors:




**Figure 6. Proposed model illustrating a key role for S1PR3 in regulating mechanical pain in AM nociceptors.** S1P promotes activation of S1PR3, which leads to inhibition of KCNQ2/3 currents and promotes normal mechanical pain sensitivity. Diminished S1P or S1PR3 antagonism alleviates inhibition of KCNQ2/3, leading to mechanical pain hyposensitivity.





**Figure S1. Loss of S1PR3 or S1P selectively impairs mechanonociception.** Related to Figure 2. A. Time to righting in seconds for N = 6 P7 pups per genotype for WT and KO mice;  $p = 0.575$  (two-tailed unpaired t-test). B. Baseline radiant heat measurements for WT, HET, and KO mice. N = 8 WT, 3 HET, and 5 KO mice. 3 measurements from both paws were averaged for each mouse.  $p = 0.444$  (one-way ANOVA). C. (Left) Time spent scratching in response to injection of 50 mM chloroquine or PBS vehicle (VEH) in KO mice;  $p = 0.042$  (unpaired t-test; N = 3,4 mice). (Right) Time spent scratching in response to injection of 27 mM Histamine or 0.1% DMSO-PBS in KO mice;  $p = 0.019$  (unpaired t-test; N = 3,4 mice). D. Normalized paw withdrawal latencies post-injection of SKI II, TY 52156, or 0.1% DMSO-PBS vehicle into the hind paw of wild-type animals;  $p = 0.65$  (one-way ANOVA); N = 5 mice per group. Unless otherwise indicated, error bars represent mean  $\pm$  SD.



**Figure S2. S1P selectively modulates potassium tail currents to increase DRG neuron excitability.**

*Related to Figure 5.* A. Example trace of a single mCherry<sup>+</sup> neuron in S1P before and after current injection. B. Rheobase pre- and post-S1P application in DRG neurons;  $p_{WT} = 0.011$ ;  $p_{KO} = 0.28$  (two-tailed paired t-test). Same data are represented in Figure 5A. C. %  $\Delta$  in instantaneous sodium current after S1P or 1% DMSO vehicle application for medium-diameter mCherry<sup>+</sup> neurons;  $p = 0.39$  (two-tailed paired t-test; N = 7 cells per group). D. %  $\Delta$  in steady-state current after S1P or 1% DMSO vehicle application for medium-diameter mCherry<sup>+</sup> neurons;  $p = 0.948$  (two-tailed paired t-test; N = 7 cells per group). E. Resting membrane potential (RMP) in millivolts before and after addition of S1P ( $p = 0.23$ ; two-tailed paired t-test; N = 6 cells). F. Dose-response relationship between %  $\Delta$  in tail current and S1P concentration for 1 nM, 50 nM, 100 nM, and 1  $\mu$ M S1P (N = 7 cells). EC<sub>50</sub> (48.8 nM), marked by thin dotted lines, was estimated from sigmoidal fit (thick dotted line).